Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants

The quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) and 9-valent HPV (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccines have demonstrated efficacy, immunogenicity, and safety in international clinical trials. We report outcomes from three completed clinical trials in India: a single-arm study (V...

Descripción completa

Detalles Bibliográficos
Autores principales: Garland, Suzanne M., Anagani, Manjula, Bhatla, Neerja, Chatterjee, Sukanta, Lalwani, Sanjay, Ross, Cecil, Group, Thomas, Lin, Jianxin, Luxembourg, Alain, Walia, Anuj, Tu, Yingmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
HPV – Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746475/
https://www.ncbi.nlm.nih.gov/pubmed/35997582
http://dx.doi.org/10.1080/21645515.2022.2105067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746475/
https://www.ncbi.nlm.nih.gov/pubmed/35997582
http://dx.doi.org/10.1080/21645515.2022.2105067

Ejemplares similares